The method for intra-operative myocardial revascularization of a human heart includes a inserting a portion of an elongated flexible lasing apparatus into the chest cavity of a patient, and lasing channels from the epicardium through the myocardium of the heart, without mechanical tearing of the heart tissue. The apparatus is guided to an area exterior to a ventricle of the patient's heart, and the distal end of the optical fiber apparatus is directed to an area of interest where the exterior wall of the heart is irradiated with laser energy to form a channel through the myocardium.

Patent
   5925033
Priority
Dec 18 1990
Filed
Oct 31 1995
Issued
Jul 20 1999
Expiry
Dec 18 2010
Assg.orig
Entity
Small
25
15
all paid
6. A minimally invasive procedure for treating a region of an outer ventricular wall of a patient's heart, comprising;
a) providing an elongated flexible energy delivering device having an elongated shaft, a proximal end, a distal end and a surface at the distal end to emit energy to ablate tissue;
b) introducing into a cavity of the patient's chest through a small opening therein a distal portion of the elongated flexible energy delivering device with the means at the distal end to emit energy;
c) directing the distal portion of the elongated flexible energy delivering device within the patient's chest cavity until the surface to emit energy at the distal end contacts the exterior of the outer ventricular wall; and
d) emitting energy to ablate tissue in the myocardium of the outer ventricular wall of the patient's heart.
1. A minimally invasive procedure for increasing blood flow to a region in an outer ventricular wall of a patient's heart, comprising;
a) providing an elongated flexible energy delivering device having an elongated shaft, a proximal end, a distal end and a surface on the distal end configured for emission of energy to ablate tissue in the outer ventricular wall of the patient's heart;
b) introducing a distal portion of the elongated flexible energy delivering device into the patient's chest through a small opening therein;
c) directing the distal portion of the elongated flexible energy delivering device within the patient's chest cavity until the surface configured to emit energy at the distal end of the device contacts the outer ventricular wall; and
d) emitting energy from said surface to ablate tissue in the outer ventricular wall of the patient's heart.
5. A minimally invasive procedure for increasing blood flow to a region in an outer ventricular wall of a patient's heart, comprising:
a) providing an elongated flexible energy delivering device having a distal end and a surface at the distal end to emit energy which penetrates into the outer ventricular wall of the patient's heart ablating tissue therein;
b) introducing a distal portion of the elongated flexible energy delivering device with the surface to emit energy at the distal end into the patient's chest through a small opening therein;
c) directing the distal portion of the elongated flexible energy delivering device within the patient's chest cavity until the surface to emit energy at the distal end thereof contacts the exterior of the ventricular wall; and
d) penetrating the outer ventricular wall of the patient's heart at least into a myocardial layer with energy emitted from said energy emitting surface to ablate tissue at least in the myocardial layer.
2. The procedure of claim 1 further including contacting said ventricular wall with the energy emitting surface in a plurality of locations to ablate tissue in the ventricular wall at the plurality of locations.
3. The procedure of claim 1 further including the steps of directing laser energy from a source thereof through the elongated flexible energy delivering device to the distal end thereof and controlling the emission of laser energy from said distal end to form a laser beam which penetrates into the ventricular wall and ablates tissue therein.
4. The procedure of claim 3 wherein laser energy is directed through the elongated energy delivering device and a lens at the distal end of the device controls the emission of laser energy.

This is a continuation application of application Ser. No. 08/361,787, now U.S. Pat. No. 5,554,152, which was filed on Dec. 20, 1994, which is a continuation of Ser. No. 08/079,699, filed on Jun. 16, 1993, now U.S. Pat. No. 5,380,316, which is a continuation of Ser. No. 07/630,259, filed on Dec. 18, 1990 (now abandoned).

This invention is generally directed to the field of laser surgery, and more particularly to laser surgery procedures to improve the flow of blood to the heart muscle.

The number and variety of medical methods available to repair the effects of cardiovascular disease has increased rapidly over the last several years. More particularly, alternatives to open heart surgery and cardiovascular by-pass surgery have been extensively investigated, resulting in non-surgical procedures such as percutaneous transluminal coronary angioplasty, laser angioplasty, and atherectomy. These procedures are primarily directed toward the reduction of stenosis within the vasculature of a patient by either expanding the lumen through the use of a balloon, or ablating or otherwise removing the material making up the stenosis.

While these procedures have shown considerable promise, many patients still require bypass surgery due to such conditions as the presence of extremely diffuse stenotic lesions, the presence of total occlusions and the presence of stenotic lesions in extremely tortuous vessels. Also, some patients are too sick to successfully undergo bypass surgery, and because the above treatments require surgical backup in the case of complications, they are untreatable. Some patients requiring repeat bypass surgeries are also untreatable.

One alternative to these procedures is known as Laser Myocardial Revascularization (LMR). In LMR, channels are formed in the ventricle wall with a laser. These channels provide blood flow to ischemic heart muscle. A history and description of this method is presented by Dr. M. Mirhoseini and M. Cayton in "Lasers in Cardiothoracic Surgery" in Lasers in General Surgery (Williams & Wilkins; 1989) pp. 216-223.

In the procedure described therein, a CO2 laser is used to produce channels in the ventricle from the epicardium through to the myocardium. This procedure follows a surgical cutdown. External pressure is used to stop bleeding from the ventricle to the outside. Dr. Mirhoseini has documented that although the channel is sealed at the epicardial layer, it remains patent in the endocardial and myocardial layers. Laser energy is transmitted from the laser to the epicardium by means of an articulated arm device that is commonly used for CO2 laser surgery.

A proposed improvement in the design is described in Hardy--U.S. Pat. No. 4,658,817. A needle is added to the distal tip of the articulated arm system, with laser energy passing through the lumen of the needle. The metal tip of the needle of the device is used to pierce most of the myocardium and the laser beam is used to create the desired channel through the remaining portion of the myocardium and through the adjacent endocardium.

Hardy contends that mechanical piercing serves to facilitate sealing of the epicardial portion of the channel. Mechanical piercing is highly undesirable, because such piercing always entails some degree of tearing of the pierced tissue. Tearing leads to fibrosis as the mechanical tear heals. Fibrosis severely diminishes the effectiveness of the LMR treatment.

These LMR procedures still require that the chest wall be opened in order to access the heart muscle with presently utilized laser devices. Thus these procedures require major surgery which is highly invasive and which may result in severe complications.

An additional problem associated with those procedures utilizing an articulated arm device is that the articulated arm is difficult to manipulate. Thus portions of the heart may be effectively unreachable by the device.

Broadly, it is the object of the present invention to provide an improved method for performing laser myocardial revascularization.

It is a further object of the present invention to provide a less invasive method for performing laser myocardial revascularization.

It is a still further object of the present invention to provide a method for performing laser myocardial revascularization which can access difficult to reach portions of the heart.

It is a yet further object of the present invention to provide a method for performing laser myocardial revascularization which does not require mechanical perforation of heart tissue.

These and other objects of the present invention will be apparent to those skilled in the art from the following detailed description and the accompanying drawings.

The present invention comprises a method of intra-operative myocardial revascularization of the myocardium of the heart of a patient. An elongated flexible lasing apparatus is inserted into the chest cavity of the patient. The distal end of the lasing apparatus is then guided to an area immediately adjacent and exterior to the patient's heart. The exterior wall of the heart is next irradiated with laser energy emitted from the distal end of the lasing apparatus with sufficient energy and for a sufficient time to cause a channel to be formed from the exterior surface of the epicardium through the myocardium and the endocardium. An exterior portion of the channel is then sealed.

FIG. 1 is a schematic section of a human heart showing revascularization of the myocardium according to the invention.

FIG. 2 is a schematic cross-section of an elongated flexible lasing apparatus suitable for the method of the invention.

FIG. 3 is a cross-section of a preferred lens design for the invention.

As is shown in the drawings, which are provided for purposes of illustration and not by way of limitation, an apparatus suitable for implementing the present invention is embodied in a system for revascularization of the myocardium of a human heart 10. As is illustrated in FIG. 1, the elongated flexible lasing apparatus 12 is placed adjacent to an area such as a ventricle 16 having an area 18 in need of increased blood circulation due to cardiovascular disease. Lasing apparatus 12 may include either an optical fiber adapted to a laser or a waveguide adapted to a CO2 laser or other laser. Portions of the heart other than ventricles might also be revascularized by this method. A number of channels 20 can be formed by the shapeable elongated flexible lasing apparatus from the outer wall, or epicardium 26, and extend a through the myocardium 24 and perforating the interior of the heart wall, the endocardium 22.

The elongated flexible lasing apparatus 12 includes a remotely located source of laser energy 30 connected to the proximal end 34 of an optical fiber 32. Laser 30 may typically be a CO2 laser, or an HO YAG laser, for example, although other sources of energy, such as excimer lasers, are adaptable to the invention. CO2 lasers would require an appropriate optical waveguide 32. Optical fiber 32 conducts the laser energy to its distal end 36.

Referring to FIG. 2, a lens 38 having a sleeve 40, is preferably connected to the distal end 36 of optical fiber 32. Although lens 38 is illustrated in FIG. 2 as being a ball type lens, the preferred embodiment of lens 38 is illustrated in FIG. 3, which is discussed below. Lens 38 controls the output spatial distribution of the laser energy emitted by optical fiber 32.

In a preferred embodiment of an apparatus adapted for the present method, a portion of distal end 36 of optical fiber 32 is adapted to be shaped into a desired configuration. Such a shapeable fiber apparatus is disclosed in co-pending application U.S. Ser. No. 07/605,774 by Samson, assigned to Advanced Cardiovascular Systems. A tubular metallic braid 37 (only shown is part) is placed over and affixed to a section of distal end 36 of optical fiber 32. This allows optical fiber 32 to retain its shape in a desired configuration.

Referring to FIG. 3, it has been found that in a preferred embodiment of the invention, a lens 350 is configured to include an essentially cylindrical outer surface 352 terminating in a convex distal tip 354. An optical fiber 332 extends into an internal cavity 356 and terminates in a position spaced apart from an internal aspheric or ogival shaped surface 358, the cavity apex 360 of which is distal from distal end 336 of fiber 332. The interface 362 between optical fiber 332 and lens 350 is reinforced, preferably with epoxy 364 or the like, although other means of reinforcement designed to prevent dislodging of the lens are adaptable to the invention.

The basic method of the present invention has been laid out above. The shapeable elongated flexible lasing apparatus 12 is inserted into the chest cavity. This insertion may require only a small incision, which would minimize the invasiveness of the procedure. Lasing apparatus 12 is then placed adjacent an area such as a ventricle 16 having an area 18 in need of increased blood circulation due to cardiovascular disease. This placement may be facilitated by shaping the fiber into a desired configuration. A number of channels 20 can then be formed by the shapeable elongated flexible lasing apparatus 12 from the outer wall, or epicardium 26, and extend through the myocardium 24 and perforating the interior of the heart wall, the endocardium 22.

In operation, the distal end of the optical fiber apparatus may be maintained in position on the outer heart wall by a gentle pressure, to insure that the apparatus is not dislodged in the formation of the channel between pulses of the laser. The heart beat is preferably monitored, and the laser is preferably gated to generate one or more pulses during contractions (systole) of the heart, and to generate no pulses during the rest of the heart cycle. These procedures combine to anchor the apparatus to a relatively stable location on the tissue that is to be ablated.

In early experiments with a HO laser, it was found that it may be desirable to begin the procedure with approximately 0.65 j pulses, at a frequency of at least 2 Hz, in order to penetrate the endocardium, and then decrease the laser power to approximately 0.2 j to form the channel in the myocardium. This minimizes the need for anchoring the catheter to the area to be treated. Note that the dosimetry is dependent upon the diameter of the lens used.

In practice, it has been found that the lens of the embodiment of FIG. 3, when in contact with tissue, cuts a lumen equal or greater than the lens diameter which is in front of and axially aligned with the axis of the lens. This provides improved ablation of channels into the heart muscle of the type preferred in this method. As the channel is cut, the cylindrical outer surface 352 assists in guiding and controlling the catheter during the cutting process. The angle of the projected energy from the lens can also be controlled by some degree with the separation of distal tip 336 of optical fiber 332 from the cavity distal apex 360. It has also been found that the construction is scalable.

It has been found that channels that are approximately 1.5 mm-2.0 mm in diameter and approximately 1 to 3 cm deep may easily and efficiently be cut by this method, and that the revascularization procedure dramatically improves the flow of blood to the heart muscle, thereby decreasing the probability of heart attack from occlusion of the external vasculature of the heart.

There has been described herein a method of performing laser revascularization of the heart. Various modifications to the present invention will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Accordingly, the present invention is to be limited solely by the scope of the following claims.

Aita, Michael, Mirhoseini, Mahmood, Cayton, Mary, Simpson, Carl J., Guscott, Brian

Patent Priority Assignee Title
10492864, Nov 18 2009 Boston Scientific Scimed, Inc. Methods and apparatus related to a distal end portion of an optical fiber having a substantially spherical shape
6281175, Sep 23 1997 Boston Scientific Scimed, Inc Medical emulsion for lubrication and delivery of drugs
6290709, Mar 06 1997 Boston Scientific Scimed, Inc Transmyocardial revascularization catheter and assembly
6363939, Jun 19 1996 Wilk Patent Development Corp. Coronary artery by-pass method
6391832, Sep 23 1997 Boston Scientific Scimed, Inc Medical emulsion for lubrication and delivery of drugs
6546932, Apr 05 1999 Medtronic Cryocath LP Cryogenic method and apparatus for promoting angiogenesis
6595958, Aug 08 2000 Boston Scientific Scimed, Inc Tortuous path injection device and method
6613017, Aug 08 2000 Boston Scientific Scimed, Inc Controlled depth injection device and method
6808498, Feb 13 1998 Medtronic, Inc Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber
6893421, Aug 08 2000 Boston Scientific Scimed, Inc Catheter shaft assembly
7025773, Jan 15 1999 Medtronic, Inc Methods and devices for placing a conduit in fluid communication with a target vessel
7044934, Aug 08 2000 Boston Scientific Scimed, Inc Tortuous path injection device
7137977, Oct 31 2003 ENDOPHOTONIX, INC Atraumatic laser tip for atrial fibrillation treatment
7163534, Oct 31 2003 ENDOPHOTONIX, INC Laser-based maze procedure for atrial fibrillation
7169142, Oct 31 2003 ENDOPHOTONIX, INC Malleable energy wand for maze procedure
7232437, Oct 31 2003 ENDOPHOTONIX, INC Assessment of lesion transmurality
7238179, Oct 31 2003 ENDOPHOTONIX, INC Apparatus and method for guided ablation treatment
7238180, Oct 31 2003 ENDOPHOTONIX, INC Guided ablation with end-fire fiber
7267674, Oct 31 2003 ENDOPHOTONIX, INC Apparatus and method for laser treatment
7338485, Oct 31 2003 ENDOPHOTONIX, INC Cardiac lesions with continuity testing
7399294, Aug 08 2000 Boston Scientific Scimed, Inc Controlled depth injection device
7578828, Jan 15 1999 Medtronic, Inc. Methods and devices for placing a conduit in fluid communication with a target vessel
7625356, Aug 08 2000 Boston Scientific Scimed, Inc. Tortuous path injection device
7993356, Feb 13 1998 Medtronic, Inc. Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication
8512360, Feb 13 1998 Medtronic, Inc Conduits for use in placing a target vessel in fluid communication with source of blood
Patent Priority Assignee Title
4469098, Dec 18 1978 Apparatus for and method of utilizing energy to excise pathological tissue
4658817, Apr 01 1985 Children's Hospital Medical Center Method and apparatus for transmyocardial revascularization using a laser
4669467, Mar 22 1985 Massachusetts Institute of Technology Mode mixer for a laser catheter
4860743, Dec 09 1983 University of Florida Research Foundation, Incorporated Laser method and apparatus for the recanalization of vessels and the treatment of other cardiac conditions
4890898, Aug 18 1988 FISMA CORPORATION Composite microsize optical fiber-electric lead cable
4917084, Jul 31 1985 CARDIOFOCUS, INC Infrared laser catheter system
4967745, Mar 22 1985 Massachusetts Institute of Technology Multi-fiber plug for a laser catheter
4985029, Jan 11 1989 Laser apparatus for medical treatment
5037421, Aug 19 1988 LUMENIS, LTD Mid-infrared laser arthroscopic procedure
5093877, Oct 30 1990 Eclipse Surgical Technologies, Inc Optical fiber lasing apparatus lens
5125926, Sep 24 1990 PLC MEDICAL SYSTEMS, INC Heart-synchronized pulsed laser system
5147354, Aug 19 1988 LUMENIS, LTD Mid-infrared laser endoscope
5380316, Dec 18 1990 HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT Method for intra-operative myocardial device revascularization
5389096, Dec 18 1990 HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT System and method for percutaneous myocardial revascularization
5554152, Dec 18 1990 HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT Method for intra-operative myocardial revascularization
//////////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 31 1995CardioGenesis Corporation(assignment on the face of the patent)
Aug 23 1999CardioGenesis CorporationEclipse Surgical Technologies, IncASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0102470272 pdf
Jun 30 2011CardioGenesis CorporationGENERAL ELECTRIC CAPITAL CORPORATION, AS AGENTSECURITY AGREEMENT0265400064 pdf
Nov 18 2015GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENTHEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENTASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT0371460466 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTCryoLife Acquisition CorporationRELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTCARDIOGENESIS CORPORATION N K A CRYOLIFE, INC RELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTCRYOLIFE, INC RELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTON-X LIFE TECHNOLOGIES, INC F K A MCRI, INC RELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTVALVE SPECIAL PURPOSE CO , LLCRELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Dec 01 2017HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENTHEMOSPHERE, INC RELEASE OF SECURITY INTEREST IN PATENTS0446210240 pdf
Date Maintenance Fee Events
Jan 21 2003M2551: Payment of Maintenance Fee, 4th Yr, Small Entity.
Jan 02 2007M2552: Payment of Maintenance Fee, 8th Yr, Small Entity.
Dec 21 2010M2553: Payment of Maintenance Fee, 12th Yr, Small Entity.


Date Maintenance Schedule
Jul 20 20024 years fee payment window open
Jan 20 20036 months grace period start (w surcharge)
Jul 20 2003patent expiry (for year 4)
Jul 20 20052 years to revive unintentionally abandoned end. (for year 4)
Jul 20 20068 years fee payment window open
Jan 20 20076 months grace period start (w surcharge)
Jul 20 2007patent expiry (for year 8)
Jul 20 20092 years to revive unintentionally abandoned end. (for year 8)
Jul 20 201012 years fee payment window open
Jan 20 20116 months grace period start (w surcharge)
Jul 20 2011patent expiry (for year 12)
Jul 20 20132 years to revive unintentionally abandoned end. (for year 12)